iPrEx Study Results:

HANC and the DAIDS-funded HIV/AIDS Clinical Trials Networks congratulates the iPrEx study team on the results which "shows that individuals at high risk for HIV infection who took a single daily tablet containing two widely used HIV medications, emtricitabine and tenofovir (FTC/TDF), experienced an average of 43.8% fewer HIV infections than those who received a placebo pill (95% CI 15.4 to 62.6%; P=0.005). The study, reported in the New England Journal of Medicine, is the first evidence that this new HIV prevention method, called pre-exposure prophylaxis or PrEP, reduces HIV infection risk in people."  

HANC has collated network statements relating to the iPrEx study findings. Press releases and links can be found below.